The Impact of Ustekinumab Biosimilar on Therapeutic Strategies in Crohn's Disease: A Paradigm Shift?
作者信息
Bezzio C, Armuzzi A
机构信息
IBD Unit, Gastroenterology Department, IRCCS Humanitas Research Hospital, Rozzano, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
出版信息
United European Gastroenterol J. 2025 Mar;13(2):177-178. doi: 10.1002/ueg2.12717. Epub 2024 Nov 30.
Abstract
摘要
相似文献
1
The Impact of Ustekinumab Biosimilar on Therapeutic Strategies in Crohn's Disease: A Paradigm Shift?乌司奴单抗生物类似药对克罗恩病治疗策略的影响：是一种范式转变吗？
United European Gastroenterol J. 2025 Mar;13(2):177-178. doi: 10.1002/ueg2.12717. Epub 2024 Nov 30.
2
The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.2018年炎症性肠病对加拿大的影响：直接成本与医疗服务利用情况
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S17-S33. doi: 10.1093/jcag/gwy055. Epub 2018 Nov 2.
3
Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey.生物类似药在炎症性肠病患者管理中的益处：一项国际调查。
J Clin Med. 2024 May 24;13(11):3069. doi: 10.3390/jcm13113069.
4
Unlocking hope: The future of ustekinumab biosimilars in Crohn's disease treatment.开启希望：优特克单抗生物类似药在克罗恩病治疗中的未来
United European Gastroenterol J. 2025 Mar;13(2):186-200. doi: 10.1002/ueg2.12682. Epub 2025 Feb 18.
5
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.瑞莎珠单抗与乌司奴单抗治疗中重度克罗恩病的疗效比较。
N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585.
6
Difficult-to-treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment.难治性炎症性肠病：4 线和 5 线治疗的有效性和安全性。
United European Gastroenterol J. 2024 Jun;12(5):605-613. doi: 10.1002/ueg2.12547. Epub 2024 Apr 9.
7
Research progress of Ustekinumab in the treatment of inflammatory bowel disease.乌司奴单抗治疗炎症性肠病的研究进展。
Front Immunol. 2024 Feb 22;15:1322054. doi: 10.3389/fimmu.2024.1322054. eCollection 2024.
8
Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations.生物类似药在炎症性肠病治疗中的应用：经济考量。
Curr Med Chem. 2019;26(2):259-269. doi: 10.2174/0929867324666170406112304.
9
Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.比较 risankizumab 和 ustekinumab 诱导和维持治疗中重度活动期克罗恩病的匹配调整间接比较。
Adv Ther. 2023 Sep;40(9):3896-3911. doi: 10.1007/s12325-023-02546-6. Epub 2023 Jun 27.
10
Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers.维持治疗中乌司奴单抗水平较高与克罗恩病的黏膜愈合和黏膜反应相关：来自 2 个 IBD 中心的经验。
Inflamm Bowel Dis. 2024 Mar 1;30(3):423-428. doi: 10.1093/ibd/izad073.
本文引用的文献
1
Unlocking hope: The future of ustekinumab biosimilars in Crohn's disease treatment.开启希望：优特克单抗生物类似药在克罗恩病治疗中的未来
United European Gastroenterol J. 2025 Mar;13(2):186-200. doi: 10.1002/ueg2.12682. Epub 2025 Feb 18.
2
The Cost of Inflammatory Bowel Disease Care: How to Make it Sustainable.炎症性肠病护理的成本：如何使其可持续发展。
Clin Gastroenterol Hepatol. 2025 Feb;23(3):386-395. doi: 10.1016/j.cgh.2024.06.049. Epub 2024 Aug 14.
3
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.瑞莎珠单抗与乌司奴单抗治疗中重度克罗恩病的疗效比较。
N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585.
4
Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF Agent.在至少接受过一种抗 TNF 药物治疗的溃疡性结肠炎患者中，乌司奴单抗与维得利珠单抗有效性的真实世界比较。
J Crohns Colitis. 2024 Oct 15;18(10):1615-1621. doi: 10.1093/ecco-jcc/jjae063.
5
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.一种生物标志物分层比较新诊断克罗恩病患者自上而下与加速阶梯治疗策略的效果（PROFILE）：一项多中心、开放标签随机对照试验。
Lancet Gastroenterol Hepatol. 2024 May;9(5):415-427. doi: 10.1016/S2468-1253(24)00034-7. Epub 2024 Feb 22.
6
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.乌司奴单抗与阿达木单抗用于生物初治中重度活动型克罗恩病患者诱导缓解和维持治疗的比较：一项多中心、随机、双盲、平行分组、3b 期临床试验。
Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2.
7
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors.对比维得利珠单抗和乌司奴单抗治疗对 TNF-α 抑制剂应答不佳的克罗恩病患者的疗效：一项真实世界研究
Am J Gastroenterol. 2022 Aug 1;117(8):1279-1287. doi: 10.14309/ajg.0000000000001773. Epub 2022 Apr 13.
8
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches.炎症性肠病生物制剂的新趋势：序贯和联合治疗方法。
Therap Adv Gastroenterol. 2021 Apr 27;14:17562848211006669. doi: 10.1177/17562848211006669. eCollection 2021.
9
Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies.护士在帮助炎症性肠病患者过渡到生物类似药方面发挥着关键作用：教育和沟通策略。
J Crohns Colitis. 2019 Feb 1;13(2):259-266. doi: 10.1093/ecco-jcc/jjy150.
Zotero 插件